NEWS
Summary
1-2 March, 2018

Event Sponsor: ICPOEP 2018

sponsors the event of the University of Hong Kong Clinical Trials Centre (HKU-CTC) for the 4th International Conference on Phase 1 and Early Phase Clinical Trials (ICPOEP).

3-4 November, 2016

Event Sponsor: ICPOEP 2016

NBI sponsors the event of the University of Hong Kong Clinical Trials Centre (HKU-CTC) for the 3rd International Conference on Phase 1 and Early Phase Clinical Trials (ICPOEP).

11 July, 2016

NBI receives HK DOH approval to proceed with a Phase 1 Clinical Trial (First in Patient) of YQ23 in patients with advanced tumors.

21 March, 2016

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of oesophageal cancer.

13 October, 2015

NBI receives UK MHRA approval to proceed with a Phase 1 Clinical Trial (First in human) of YQ23 in healthy volunteers.

19 November, 2014

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of hepatocellular carcinoma.

× We use page tagging techniques and cookies to improve the site, provide services to you, and customize your browsing experience. By continuing to browse the site you are agreeing to accept our use of cookies